These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 27072111)

  • 1. The application of proteomics in different aspects of hepatocellular carcinoma research.
    Xing X; Liang D; Huang Y; Zeng Y; Han X; Liu X; Liu J
    J Proteomics; 2016 Aug; 145():70-80. PubMed ID: 27072111
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proteomics for the early detection and treatment of hepatocellular carcinoma.
    Feng JT; Shang S; Beretta L
    Oncogene; 2006 Jun; 25(27):3810-7. PubMed ID: 16799622
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Precision Medicine: Update on Diagnosis and Therapeutic Strategies of Hepatocellular Carcinoma.
    Liang Q; Shen X; Sun G
    Curr Med Chem; 2018; 25(17):1999-2008. PubMed ID: 29345573
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic biomarkers for prediction of recurrence of hepatocellular carcinoma: current status and future prospects.
    Lee SC; Tan HT; Chung MC
    World J Gastroenterol; 2014 Mar; 20(12):3112-24. PubMed ID: 24696598
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reveal the molecular signatures of hepatocellular carcinoma with different sizes by iTRAQ based quantitative proteomics.
    Wang Y; Liu H; Liang D; Huang Y; Zeng Y; Xing X; Xia J; Lin M; Han X; Liao N; Liu X; Liu J
    J Proteomics; 2017 Jan; 150():230-241. PubMed ID: 27693406
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent progress in predictive biomarkers for metastatic recurrence of human hepatocellular carcinoma: a review of the literature.
    Qin LX; Tang ZY
    J Cancer Res Clin Oncol; 2004 Sep; 130(9):497-513. PubMed ID: 15205947
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Stable isotope labeling and parallel reaction monitoring-based proteomic quantification for biomarker screening and validation of hepatocellular carcinoma].
    Wang S; Gao H; Zhang J; Ye X
    Se Pu; 2017 Sep; 35(9):934-940. PubMed ID: 29048850
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liquid biopsy in patients with hepatocellular carcinoma: Circulating tumor cells and cell-free nucleic acids.
    Okajima W; Komatsu S; Ichikawa D; Miyamae M; Ohashi T; Imamura T; Kiuchi J; Nishibeppu K; Arita T; Konishi H; Shiozaki A; Morimura R; Ikoma H; Okamoto K; Otsuji E
    World J Gastroenterol; 2017 Aug; 23(31):5650-5668. PubMed ID: 28883691
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Proteomic-driven precision medicine research in hepatocellular carcinoma].
    Jiang Y; He FC
    Zhonghua Gan Zang Bing Za Zhi; 2022 Aug; 30(8):797-802. PubMed ID: 36207935
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current advances in tumor proteomics and candidate biomarkers for hepatic cancer.
    Peng XQ; Wang F; Geng X; Zhang WM
    Expert Rev Proteomics; 2009 Oct; 6(5):551-61. PubMed ID: 19811076
    [TBL] [Abstract][Full Text] [Related]  

  • 11. One Sample, One Shot - Evaluation of sample preparation protocols for the mass spectrometric proteome analysis of human bile fluid without extensive fractionation.
    Megger DA; Padden J; Rosowski K; Uszkoreit J; Bracht T; Eisenacher M; Gerges C; Neuhaus H; Schumacher B; Schlaak JF; Sitek B
    J Proteomics; 2017 Feb; 154():13-21. PubMed ID: 27932303
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biomarker discovery in hepatocellular carcinoma (HCC) for personalized treatment and enhanced prognosis.
    Yu B; Ma W
    Cytokine Growth Factor Rev; 2024 Oct; 79():29-38. PubMed ID: 39191624
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In-depth proteomic analysis of tissue interstitial fluid for hepatocellular carcinoma serum biomarker discovery.
    Zhang J; Hao N; Liu W; Lu M; Sun L; Chen N; Wu M; Zhao X; Xing B; Sun W; He F
    Br J Cancer; 2017 Nov; 117(11):1676-1684. PubMed ID: 29024941
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proteomic analysis and translational perspective of hepatocellular carcinoma: Identification of diagnostic protein biomarkers by an onco-proteogenomics approach.
    Chiou SH; Lee KT
    Kaohsiung J Med Sci; 2016 Nov; 32(11):535-544. PubMed ID: 27847095
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oncoproteomics of hepatocellular carcinoma: from cancer markers' discovery to functional pathways.
    Sun S; Lee NP; Poon RT; Fan ST; He QY; Lau GK; Luk JM
    Liver Int; 2007 Oct; 27(8):1021-38. PubMed ID: 17845530
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Challenges of Clinical Research on Hepatocellular Carcinoma.
    Kudo M; Kitano M; Sakurai T; Nishida N
    Dig Dis; 2015 Oct; 33(6):780-90. PubMed ID: 26488399
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proteomic and metabonomic biomarkers for hepatocellular carcinoma: a comprehensive review.
    Kimhofer T; Fye H; Taylor-Robinson S; Thursz M; Holmes E
    Br J Cancer; 2015 Mar; 112(7):1141-56. PubMed ID: 25826224
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tissue-based quantitative proteome analysis of human hepatocellular carcinoma using tandem mass tags.
    Megger DA; Rosowski K; Ahrens M; Bracht T; Eisenacher M; Schlaak JF; Weber F; Hoffmann AC; Meyer HE; Baba HA; Sitek B
    Biomarkers; 2017 Mar; 22(2):113-122. PubMed ID: 27467182
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical proteomics-driven precision medicine for targeted cancer therapy: current overview and future perspectives.
    Zhou L; Wang K; Li Q; Nice EC; Zhang H; Huang C
    Expert Rev Proteomics; 2016; 13(4):367-81. PubMed ID: 26923776
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The search for biomarkers of hepatocellular carcinoma and the impact on patient outcome.
    Black AP; Mehta AS
    Curr Opin Pharmacol; 2018 Aug; 41():74-78. PubMed ID: 29772420
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.